Escitalopram
- Generic Name
- Escitalopram
- Brand Names
- Cipralex, Lexapro
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN2O
- CAS Number
- 128196-01-0
- Unique Ingredient Identifier
- 4O4S742ANY
- Background
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...
- Indication
Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...
- Associated Conditions
- Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
- Associated Therapies
- -
Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression
- Conditions
- Interventions
- First Posted Date
- 2005-01-11
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Maurizio Fava, MD
- Target Recruit Count
- 199
- Registration Number
- NCT00101452
- Locations
- 🇺🇸
Butler Hospital, Providence, Rhode Island, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Lexapro and Pramipexole and to Treat Major Depression
- First Posted Date
- 2004-06-30
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 39
- Registration Number
- NCT00086307
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Treatment of Adolescent Suicide Attempters (TASA)
- Conditions
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 120
- Registration Number
- NCT00080158
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Columbia University at the New York State Psychiatric Institute, New York, New York, United States
🇺🇸New York University Child Study Center, New York, New York, United States
Treatment of Depression in Adults
- Conditions
- Interventions
- First Posted Date
- 2003-12-03
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 290
- Registration Number
- NCT00073697
- Locations
- 🇺🇸
Western Psychiatric Institute and Clinic - Depression Prevention Program, Pittsburgh, Pennsylvania, United States
🇮🇹The University of Pisa, Pisa, Italy
Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression
- Conditions
- First Posted Date
- 2003-11-21
- Last Posted Date
- 2007-07-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 675
- Registration Number
- NCT00073411
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Cincinnati, Ohio, United States
Preventing Post-Stroke Depression
- Conditions
- Interventions
- First Posted Date
- 2003-10-30
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Robert G. Robinson
- Target Recruit Count
- 201
- Registration Number
- NCT00071643
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Burke Rehabilitation Hospital, White Plains, New York, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.